

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 040 837 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
04.10.2000 Bulletin 2000/40

(21) Application number: 00200707.8

(22) Date of filing: 28.02.2000

(51) Int. Cl.⁷: **A61K 38/31**, A61K 9/06,
A61K 9/52, A61K 9/08,
A61K 9/10, A61P 27/02

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 26.02.1999 US 258240

(71) Applicant:
Erasmus Universiteit Rotterdam
3015 GE Rotterdam (NL)

(72) Inventors:
• Kuijpers, Robertus Wilhelmus Aloysius Maria
3023 BG Rotterdam (NL)
• van Hagen, Petrus Martinus
3062 XM Rotterdam (NL)
• Baarsma, Goitzen Seerp
3054 CM Rotterdam (NL)

(74) Representative:
Ottevangers, Sietse Ulbe et al
Vereenigde,
Nieuwe Parklaan 97
2587 BN The Hague (NL)

(54) **Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder**

(57) The invention relates to preparation of medicaments for the treatment of ocular disorders, in particular choroidal neovascularization (CNV) related disorders. The control of ocular neovascularization is regulated by a balance between stimulating and inhibiting growth factors. The anti-angiogenic effect of somatostatin analogues are used to provide a medicament for the treatment of a choroidal neovascularization (CNV) related disorder.

EP 1 040 837 A2

Description

FIELD OF THE INVENTION

- 5 [0001] The invention relates to the preparation of medicaments for the treatment of ocular disorders, in particular choroidal neovascularization (CNV) related disorders.

BACKGROUND OF THE INVENTION

- 10 [0002] Age-related maculopathy (ARM) is the major cause of blindness in people over 65 years in the Western world. The prevalence of ARM is up to 14% over age 85. Late stages of ARM, also called age-related macular degeneration (AMD), include geographic atrophy and exudative macular degeneration. The exudative form is characterized by choroidal neovascularization (CNV) and is responsible for 80% of the cases of severe vision loss. These numbers will enlarge because of the increasing average age of the population. In CNV newly formed vessels from the underlying
15 choroid grow beneath the retinal pigment epithelium (RPE) and the retina. Although the morphology of angiogenesis in CNV secondary to AMD has been described in detail, the pathogenesis is still poorly understood, if at all. A balance between a number of stimulating and inhibiting growth factors regulates the control of neovascularization (see: D'Amore PA. "Mechanisms of retinal and choroidal neovascularization", *Invest Ophthalmol Vis Sci.* 1994;35:3974-3979). Vascular endothelial growth factor (VEGF), and endothelial specific mitogen, are regarded as the most important ocular angiogenic factors, specially in ischemic disease. Other regulating growth factors include fibroblast growth factors (FGFs),
20 transforming growth factor β (TGF β) and insulin-like growth factor I (IGF-I). Most of these growth factors are shown to be upregulated in a diversity of cells (RPE, fibroblasts, capillary endothelial cells) involved in CNV.

- [0003] Smith *et al.* ("Essential role of growth hormone in ischemia-induced retinal neovascularization", *Science.* 1997;393:93-101) have shown that inhibition of growth hormone (GH), mediated by IGF-I in a transgenic mice model,
25 can inhibit ischemia-induced retinal neovascularization *in vivo*. The release of GH secretion by the pituitary gland is inhibited by somatostatin and somatostatin analogues. Systemic treatment with a somatostatin analogue diminished the level of ocular neovascularization in mice thus indirectly by intervening in the GH secretion of the pituitary gland.

[0004] Until now, no suitable methods and medicaments for the selective and/or topical or *in situ* treatment of CNV related disorders exist.

- 30 [0005] It is an object of the present invention to provide such a method and medicament.

[0006] It is a further object of the present invention to provide new medicaments for CNV related disorders that could not be treated successfully until now.

[0007] Such medicaments are of particular relevance in view of the increasing age of the population and the geriatric nature of CNV related disorders.

35

SUMMARY OF THE INVENTION

- [0008] The present inventors have found that the objects of the invention can be achieved by the administration to a patient of compounds that bind to at least one somatostatin receptor, such as sst₁, sst₂, sst₃, sst₄ or sst₅, and preferably
40 to at least the sst₂ receptor, and more preferably to the sst_{2A} receptor.

- [0009] The present inventors have found that somatostatin or somatostatin analogues directly effect angiogenesis and also have a direct anti-proliferative effect on human retinal endothelial cells. In addition, it was found that sst receptors, such as the sst_{2A} receptor, in choroid and retina of early ARM and non-neovascular AMD are localized similar to normal controls. In eyes with CNV, the sst_{2A} receptor is upregulated in the fibrovascular phase of CNV, as well as in
45 intrachoroidal myofibroblasts. Because of the sst expression in CNV, somatostatin analogues can be employed in a therapy for early stages of CNV in AMD.

DETAILED DESCRIPTION OF THE INVENTION

- 50 [0010] In accordance with the present invention, it has been found that a beneficial effect is obtained when compounds that bind to at least one somatostatin receptor in the eye are administered to patients suffering from a CNV related disorder. More in particular, if patients suffering from a CNV related disorder are treated with compounds that bind in the eye to somatostatin receptors, such as sst₁, sst₂, sst₃, sst₄ or sst₅, that the CNV related disorder will diminish or even disappear. Further, inflammation reactions decreased.

- 55 [0011] Preferably, said compound binds to somatostatin receptors in the eye in the nanomolar range.

[0012] In a preferred embodiment of the method of the invention, the said compound binds to a sst₂ receptor, most preferably to a sst_{2A} receptor.

[0013] It was known that somatostatin binds with high affinity to 5 subtype receptors (sst₁₋₅). The exact role of a

A is C₁₋₁₂alkyl, C₇₋₁₀phenylalkyl or a group of formula RCO-, whereby

- (i) R is hydrogen, C₁₋₁₁alkyl, phenyl or C₇₋₁₀phenylalkyl, or
 (ii) RCO- is

- a) a D-phenylalanine residue optionally ring-substituted by halogen NO₂, NH₂, OH, C₁₋₃alkyl and/or C₁₋₃alkoxy; or
 b) the residue of a natural or a synthetic α -amino-acid other than defined under a) above, or of a corresponding D-amino acid, or
 c) a dipeptide residue in which the individual amino acid residues are the same or different and are selected from those defined under a) and/or b) above,

the α -amino group of amino acid residues a) and b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di-C₁₋₁₂alkylated or substituted by C₁₋₈alkanoyl;

A' is hydrogen or C₁₋₃alkyl,

Y₁ and Y₂ represent together a direct bond or each of the Y₁ and Y₂ is hydrogen


B is -Phe- optionally ring-substituted by halogen, NO₂, NH₂, OH, C₁₋₃alkyl and/or C₁₋₃alkoxy (including pentafluoroalanine), naphthylalanine or pyridylalanine,

C is (L)-Trp- or (D)-Trp- optionally α -N-methylated and optionally benzene-ring-substituted by halogen, NO₂, NH₂, OH, C₁₋₃alkyl and/or C₁₋₃alkoxy,

D is Lys, 4-aminocyclohexylAla or 4-aminocyclohexylGly

E is Thr, Ser, Val, Tyr, Ile, Leu or an aminobutyric or aminoisobutyric acid residue

G is a group of formula: -COOR₇, -CH₂OR₁₀, -CONR₁₁R₁₂ or



wherein

R₇ is hydrogen or C₁₋₃alkyl,

R₁₀ is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,

R₁₁ is hydrogen, C₁₋₃alkyl, phenyl or C₇₋₁₀phenyl-alkyl,

R₁₂ is hydrogen, C₁₋₃alkyl or a group of formula -CH(R₁₃)-X₁,

R₁₃ is CH₂OH, -(CH₂)₂-OH, -(CH₂)₃-OH, or -CH(CH₃)OH or represents the substituent attached to the α -carbon atom of a natural or synthetic α -amino acid (including hydrogen) and

X₁ is a group of formula -COOR₇, -CH₂OR₁₀ or -CO-NR₁₄R₁₅ wherein

R₇ and R₁₀ have the meanings given above,

R₁₄ is hydrogen or C₁₋₃alkyl and

R₁₅ is hydrogen, C₁₋₃alkyl, phenyl or C₇₋₁₀phenylalkyl, and

R₁₆ is hydrogen or hydroxy,

with the proviso that

when R₁₂ is -CH(R₁₃)-X₁ then R₁₁ hydrogen or methyl,

wherein the residues B, D and E have the L-configuration, and the residues in the 2- and 7-position each independently have the (L)- or (D)-configuration,

in free form or in pharmaceutically acceptable salt or complex form.

[0022] Individual compounds of formula I suitable in accordance with the present invention are the following somatostatin analogues:

- a. (D) Phe-Cys-Phe- (D) Trp-Lys-Thr-Cys-Tyr-ol
also known as octreotide
- b. (D) Phe-Cys-Tyr- (D) Trp-Lys-Val-Cys-ThrNH₂
- c. (D) Phe-Cys-Tyr- (D) Trp-Lys-Val-Cys-TrpNH₂
also known as vapreotide
- d. (D) Trp-Cys-Phe- (D) Trp-Lys-Thr-Cys-ThrNH₂
- e. (D) Phe-Cys-Phe- (D) Trp-Lys-Thr-Cys-ThrNH₂
- f. 3- (2- (Naphthyl) - (D) Ala-Cys-Tyr- (D) Trp-Lys-Val-Cys-ThrNH₂
also known as lanreotide
- g. (D) Phe-Cys-Tyr- (D) Trp-Lys-Val-Cys-β-Nal-NH₂
- h. 3- (2- (Naphthyl) - (D) Ala-Cys-Tyr- (D) Trp-Lys-Val-Cys-β-Nal-NH₂
- i. (D) Phe-Cys-β-Nal- (D) Trp-Lys-Val-Cys-Thr-NH₂
- j. (D) Phe-Cys-Tyr- (D) Trp-Lys-Leu-Cys-Thr-NH₂
- k. (D) Phe-Cys-Tyr- (D) Trp-Lys-Cys-Thr-NH₂

[0023] More preferred compounds of formula (I) are compounds (a) - (k). A highly preferred compound of formula (I) is octreotide.

[0024] Compounds of formula (I) may exist e.g. in free form, salt form or in the form of complexes thereof. Acid addition salts may be formed with e.g. organic acids, polymeric acids and inorganic acids. Such acid addition salt forms include e.g. the hydrochlorides and acetates. Complexes are e.g. formed from compounds of the invention on addition of inorganic substances, e.g. inorganic salts or hydroxides such as Ca- and Zn-salts, and/or addition of polymeric organic substances.

[0025] According to the invention, the compound binding to somatostatin receptor is preferably administered in the form of a pharmaceutical composition, by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets, capsules, drink solutions, emulsions or microemulsion pre concentrates, nasally, pulmonary (by inhalation), parenterally, e.g. in the form of injectable solutions or suspensions, or topically. The compound is preferably administered topically in an ophthalmic preparation, or subcutaneously, e.g. by injection and/or infusion in the eye.

[0026] The compound capable of binding to a somatostatin is preferably administered topically to an individual, typ-

ically in the form of an ophthalmic liquid preparation (eye drop), in the form of a gel and/or in the form of an ointment.

[0027] The compound capable of binding to a somatostatin receptor may also be administered in the eye locally, e.g., intravitreally and peribulbally.

[0028] The amount administered is determined taking into account various factors such as the etiology and severity of the disease, and the patient's condition. A somatostatin analogue may be administered, e.g. subcutaneously in a dosage range of about 100 µg to 10 mg per day as a single dose or in divided doses. Thus, octreotide may be administered at a dose of from 0.2 mg to 10 mg twice or three times daily. When administered as a slow release form, such formulation may comprise the somatostatin peptide in a concentration of from 2.0 to 10% by weight. The release period of such a formulation may be from 1 week to about 2 months. Preferably the formulation in slow release form is administered intramuscularly.

[0029] It is noted that the use of octreotide in a very specific type of ocular disorder is known from Kuipers *et al.* ("Treatment of Cystoid Macular Edema with Octreotide", N Engl J Med 338(1998)624-626). In this publication a treatment of a 21 year old patient suffering from idiopathic cystoid macular edema using octreotide is described. However, nothing is taught in this publication with respect to choroidal neovascularization. In addition, this publication is directed to the treatment of a 21-year-old patient and is therefore not in the field of geriatrics. The CNV related disorders which can be treated with the medicaments of the present invention are generally associated with geriatrics.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030]

Figure 1. Immunolocalization of sst_{2A} in posterior pole of normal eyes and eyes with different stages of ARM. Immunohistochemistry was performed on paraffin-embedded tissue, and visualized with an alkaline phosphatase detection system using a red chromogen. (A) Positive staining of normal neuroretina, with strong sst_{2A} expression in the inner plexiform layer (ipl) and moderate expression in the outer plexiform layer and the cellular membrane of the inner nuclear layer (inl). (B) Sst_{2A} staining of normal RPE, showing the membranous staining pattern at the apical side. (C) Sst_{2A} staining of an eye with early ARM, showing negative staining of basal laminar deposits and soft drusen (asterixis). (D,E) Sst_{2A} staining of a mixed fibrovascular and fibrocellular CNV (eye nr 13) in an eye with AMD. Long arrow indicates positive RPE; short arrows indicate positive fibroblast-like cells. Arrowheads indicate positive endothelium of newly formed vessels. Asterixis indicates overlying neuroretina. (F) Sst_{2A} staining of a fibrocellular CNV (eye nr 16) in an eye with AMD, with no staining of endothelial cells and fibroblast-like cells. (G) Negative control staining of CNV (eye nr 13) with peptide blocking. Original magnification (A)x200, (B through H)x400. (onl = outer nuclear layer, phr = photoreceptor layer, RPE = retinal pigment epithelium, BrM = Bruch's Membrane, CC = choriocapillaris).

Figure 2. Expression of sst receptor subtype mRNA in the posterior pole of a normal human eye, detected by RT-PCR. Sst₁, sst_{2A} and sst₃ were detected, signals for sst₄ and sst₅ were too low to detect or absent. mRNA for somatostatin (SS14) was also detected. HPRT (hypoxanthine-guanine phosphoribosyl transferase) was used as internal control. (marker = 100 bas pair-marker).

[0031] The present invention will be further illustrated by the following non-limiting example.

[0032] This example was performed according to the tenets of the Declaration of Helsinki. Enucleation or surgical excision of subfoveal CNVs was performed after obtaining informed consent of the patient.

EXAMPLE

[0033] Patients All eyes were retrieved from the files from the ophthalmic pathology department of the University Hospital of Rotterdam. Sixteen eyes (ten enucleated eyes, four donor eyes and two surgically removed subretinal neovascular membranes) of fifteen patients with different stages of ARM were used for immunohistochemistry. The description of each eye is given in Table 1.

Table 1. Patient material and sst_{2A} receptor expression in eyes with ARM

Nr	Age/ sex	OD/ OS	Clinical description	Histological classification	Sst _{2A} expression*						
					Preexistent tissue			Neovascular tissue			
					RPE	CC	CH	CNV	EC	FBL	
1	85/M	OS	neovascularising sclero-kerato-malacia	early ARM: BLD	++	0	++	NP	.	.	
2	98/F	OS	corneal ulcer	early ARM: confluent soft drusen	++	+	++	NP	.	.	
3	96/F	OD	staphyloma, suspect ciliary body melanoma	early ARM: BLD; glaucoma corneal ulcer	++	0	+	NP	.	.	
4	77/M	OS	neovascular glaucoma	non-neovascular AMD; early geographic atrophy; occlusion central retinal artery; ischemic retinal disease	++	0	+	NP	.	.	
5	73/M	OD	disconform MD, post-irradiation	subretinal CNV, FV	+	0	++	FV	++	+	
6	85/F	OS	post-surgical endophthalmitis	subretinal CNV, FV, endophthalmitis, uveitis	+	0	+	FV	NC	+	
7	79/M	U	surgically excised CNV	mixed CNV, FV and FC, HEM	NP	NP	NP	FV	++	++	
8	79/F	U	surgically excised CNV	subretinal CNV, FV and FC, HEM	NP	NP	NP	FC	NP	0	
								FV	++	++	
								FC	+	++	

Table 1 continued

Nr	Age/ sex	OD/ OS	Clinical description	Histological classification	SstA expression*							
					Preexistent tissue Neovascular tissue							
					RPE	CC	CH	CNV	EC	FBL		
9	72/M	OS	disciform MD	mixed CNV, BLD, FV and FC, HEM	+	0	+	FV	+	+		
10	86/M	OS	disciform MD, acute glaucoma	sub-RPE CNV, BLD, FV and FC, HEM; retinal detachment; posterior uveitis	++	+	++	FV	NP	NP		
11	87/M	OS	donor eye	disciform MD, mixed subretinal and sub-RPE CNV, BLD, FV and FC	++	+	++	FV	+	+		
12	83/M	OD	painful eye, suspect uveal melanoma	ischemic retinal disease; disciform MD, mixed CNV, BLD, FV and FC, HEM	++	0	+	FV	++	++		
13	73/M	OS	disciform MD	subretinal CNV, FC and FV	++	0	+	FV	++	++		
14	84/F	OS	disciform MD	mixed CNV, FV and FC, HEM	+	0	+	FV	+	+		
15	91/M	OS	donor eye	disciform MD, mixed CNV, BLD, FC	NC	0	NC	FC	0	0		
16	82/m	OD	disciform MD	mixed CNV, confluent soft drusen, FC	+	0	0	FC	0	0		

Table 1: Patient material and sst_{2A} receptor expression in eyes with ARM

*Category of sst_{2A} expression: 0 = 0 - 10% positive cells; + = 11% positive cells; ++ = 51 - 100% positive cells. (MD = macular degeneration; mixed CNV = mixed subretinal and sub-RPE CNV; FV = fibrovascular CNV; FC = fibrocellular scar; BLD = basal laminar deposits; HEM = hemorrhage. RPE = retinal pigment epithelium; CC = choriocapillaris; CH = choroidal vessels; CNV = choroidal neovascularisation; EEC = endothelial cells; FBL = fibroblasts-like cells.

U = unknown; NC = not classified; NP = not present)

[0034] Eight eyes (of seven patients) were clinically diagnosed as AMD. In eight eyes, ARM was diagnosed histopathologically according to the following criteria. Early stages of ARM were characterized by the presence of basal laminar deposits, basal linear deposits (BLD), soft drusen and thickening of Bruch's membrane (n=3). Exudative AMD was classified as sub-RPE CNV, subretinal CNV (between neuroretina and RPE) or mixed sub-RPE and subretinal CNV (n=12). Photoreceptors, Bruch's membrane and BLD were helpful in the orientation of the specimens. Sub-RPE CNV and mixed CNV, or subretinal CNV in elderly patients in the presence of BLD or soft drusen were classified as CNV secondary to AMD. In CNV, we recorded the presence of fibrovascular or fibrocellular tissue, hemorrhage, vascular endothelium, BLD and RPE. On eye was classified as non-neovascular (geographic) AMD. Eight enucleated eyes without ARM (donor-eyes or enucleated for other reasons) were used as controls (Table 2).

Table 2. Patient material and sst receptor subtype expression in normal eyes

Nr	Age/ sex	OD/ OS	Clinical description	Sst receptor subtype expression*										Sst _{1A} expression†			
				(RT-PCR)										(immunohistochemistry)			
				Sst ₁	Sst _{1A}	Sst ₂	Sst ₃	Sst ₄	Sst ₅	SS14	HPRT	RPE	CC	CH			
1	71/U	OD	donor-eye	++	+	++			
2	51/M	OD	ciliary body melanoma	+	0	+			
3	78/M	OS	choroidal melanoma	++	0	+			
4	81/M	OS	tarsal squamous cell carcinoma	+	+	++			
5	42/M	OS	choroidal melanoma	++	0	++			
6	76/F	OS	choroidal melanoma	++	0	++			
7	57/M	OS	recurrent conjunctival melanoma	+	0	+			
8	60/M	OS	choroidal melanoma	++	0	++			
9	69/M	OD	ciliary body adenoma	+	+	+	+	+	+	+	+	.	.	.			
10	78/M	OS	spindle cell nevus	+	+	+	+	+	+	+	+	.	.	.			
11	26/M	OS	choroidal melanoma	+	+	+	+	+	+	+	+	.	.	.			

Table 2: Patient material and sst receptor subtype expression in normal eyes

*Category of sst subtype expression (RT-PCR): - = no expression, + = positive expression.
 †Category of sst_{2A} expression (immunohistochemistry): 0 = 0 - 10% positive cells;
 + = 11 - 50% positive cells; ++ = 51 - 100% positive cells.
 (SS14 = somatostatin; HPRT = hypoxanthine-guanine phosphoribosyl transferase; RPE = retinal pigment epithelium; CC = choriocapillaris; CH = choroidal vessels. U = unknown)

[0035] The eyes were processed for routine diagnostic procedures by fixation in formaldehyde and embedded in paraffin.

Immunohistochemistry

[0036] Rabbit anti-human somatostatin receptor 2A polyclonal antibody was kindly provided by A. Schonbrunn, (Dept. of Pharmacology, University of Texas, Houston, USA). The sst_{2A} antibody was raised against a 22-aminoacid peptide located in the C-terminal region of the sst₂ receptor. The sst_{2A} antibody was characterized and tested before by Western blot analysis and peptide binding. Mouse monoclonal antibody against smooth muscle actin (sma) was obtained from Biogenex, San Ramon, CA, USA; mouse monoclonal antibody against macrophages (CD68) from Dako, Glostrup, Denmark. Five µm sections were prepared. The sections were dewaxed, rehydrated and (for sst_{2A} and CD68) microwave-heated for 10 minutes. After blocking with normal goat serum (Dako, 1:10) for 15 minutes, the slides were incubated with sst_{2A} antibody (1:1000) or CD68 antibody (1:2000) overnight at 4°C, or with anti-sma (1:150) for 1 hour at room temperature. The sections were further incubated biotinylated multilink antibodies for 30 minutes, followed by alkaline phosphatase-labeled antibiotin (both Biogenex) for 30 minutes. The bound antibodies were visualized by incubating the sections with New Fuchsin for 30 minutes in the dark. The slides were counterstained with Mayer's hematoxylin, mounted and examined by light microscopy. The sst_{2A} expression was graded in 3 categories: 0 (0-10% positive cells), 1 (11-50% positive cells) and 2 (51-100% positive cells). Negative controls for immunohistochemistry included 1) omission of the primary antibody, 2) use of an irrelevant antibody of the same isotype, and 3) preabsorption of the sst_{2A} antibodies with the immunizing receptor peptide for 4 hours; at a concentration of 3 µg/ml.

RT-PCR

[0037] In order to study the mRNA expression of sst subtypes in normal human eyes, posterior poles from three eyes (Table 2) were dissected directly after enucleation. A sample of about 0.2 mm² localized in the macula, including RPE, choroid and sclera, was snap-frozen in liquid nitrogen. RT-PCR was performed as described by Ferone *et al.* ("In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells". Endocrinology, 1999;140:373-380) the nucleotide sequences of the primers used are given in Table 3.

Table 3

Primers used for RT-PCR analysis			
receptor	primer	sequence (5'-3')*	product size (base pair)
sst ₁	forward	ATGGTGGCCCTCAAG-GCCGG	318
	reverse	CGCGGTGGCGTAAT-AGTCAA	
sst _{2A}	forward	GCCAAGATGAAGACCAT-CAC	414
	reverse	GATGAACCCTGTGTAC-CAAGC	
sst ₃	forward	CCAACGTCTACATCCT-CAACC	314
	reverse	TCCCGAGAAGACCAC-CAC	
sst ₄	forward	ATCTTCGAGACACCA-GACC	321
	reverse	ATCAAGGCTGGTCAC-GACGA	
sst ₅	forward	CGTCTTCATCATCTA-CACGG	226
	reverse	CCGTCTTCATCATCTA-CACGG	
SS14	forward	GATGCTGTCCT-GCCGCCTCCAG	349
	reverse	ACAGGATGTGAAAGTCT-TCCA	
HPRT	forward	CAGGACTGAACGTCTT-GCTC	413
	reverse	CAAATCCAACAAAGTCT-GGC	

Table 3: Primers used for RT-PCR analysis

The sequences of the primers for sst₁ were derived and adapted from Wulfsen *et al.*, for sst₅ from Kubota *et al.*, and all others were designated by use of the Primer3!software (http://www-genome.wi.mit.edu/genome_software/other/primer3.html) and the appropriate GenBank entries. (SS14 = somatostatin; HPRT = hypoxanthine-guanine phosphoribosyl transferase)

[0038] Several controls were included in the RT-PCR experiments. To ascertain that no detectable genomic DNA was present in the polyA⁺ mRNA preparation (since the sst genes are intron-less), the cDNA reactions were also performed without reverse transcriptase and amplified with each primer-pair. Amplification of the cDNA samples with the HPRT (hypoxanthine-guanine phosphoribosyl transferase) specific primers served as positive control for the quality of the cDNA. To exclude contamination of the PCR reaction mixtures, the reactions were also performed in the absence of DNA template in parallel with cDNA samples. As a positive control for the PCR reactions of the sst receptor subtypes, 0.1 to 0.001 µg of human genomic DNA, representing approximately 30.000 to 300 copies of sst-template, was amplified in parallel with the cDNA samples. As a positive control for the PCR of the HPRT gene and somatostatin cDNA aliquots of a cDNA sample known to contain somatostatin and HPRT mRNA were amplified, because these primer-pairs did enclose introns in the genomic DNA.

Results

[0039] In normal retina (n=8) high sst_{2A} expression was found in the inner plexiform layer (IPL) and moderate expression was found in the outer plexiform layer (OPL), the cellular membrane of the inner nuclear layer (INL) (Figure 1A), and the RPE. RPE stained most frequently at the apical side in a membranous pattern (Figure 1B), which was also noted in tangentially cut sections. Thick walled choroidal vessels stained mostly positive, whereas choriocapillaris stained only sporadically (Table 1). In negative controls, no staining was detected.

[0040] In the eyes with early ARM (n=3), sst_{2A} expression of the neuroretina, choroidal vessels and choriocapillaris was similar to normal controls (Table 1). The RPE stained positive in all cases, BLD were negative (Figure 1C).

[0041] In eyes with exudative AMD (n=12) Bruch's membrane and BLD did not show sst_{2A} expression (Table 1). The choriocapillaris showed focal expression in only two eyes. Approximately 50-75% of choroidal arteries stained positive, which was similar to normal controls. The CNV, both surgically excised and in enucleated eyes, could be subdivided in three groups, regarding the activity of neovascularization: the first group consisted of fibrovascular tissue with inflammatory cells, fibroblast-like cells and sparse fibrosis (n=2). The second group consisted of fibrocellular scar tissue (n=2), and the third group consisted of a mixture of both fibrovascular and fibrocellular tissue (n=8).

[0042] In the CNV monolayers of pigmented cells adjacent to BLD were scored as RPE cells. About half of these morphologically RPE cells showed sst_{2A} expression (Figure 1D). The expression of sst_{2A} in newly formed endothelial cells was upregulated in fibrovascular membranes. Similarly, sst_{2A} was upregulated in endothelial cells of mixed fibrovascular membranes (Figure 1E). Fibroblast-like cells and macrophages stained highly positive in young membranes, less strongly in elder scars (Figure 1D and E). Little or negative staining was observed in old hypocellular scars (Figure 1F). Peptide blocking significantly decreased staining of all structures mentioned (Figure 1G).

[0043] In one eye with a mixed fibrovascular and fibrocellular membrane (eye number 12), we found positive staining of myofibroblasts in a hypercellular area of the underlying choroid in the posterior pole. This area also stained positive with antibodies directed against sma and CD68, confirming the presence of myofibroblastic cells and macrophages.

[0044] In the eye with non-neovascular AMD, the staining pattern was similar to control tissue. The RPE stained positive. No staining was seen in the choriocapillaris, and vessels in the choroid were mostly positive.

[0045] RT-PCR analysis of 3 posterior poles, including retina, RPE, choroid and sclera, revealed that mRNA encoding for sst₁, sst_{2A}, sst₃ and somatostatin is expressed in the posterior pole of normal human eye. No mRNA encoding for sst₄ or sst₅ could be detected (Figure 2, Table 2).

[0046] From this Example it follows that normal human eyes and eyes with early and late stages of ARM express sst_{2A}. The localization of sst_{2A} expression in the neuroretina physiological neuromodulator-function of somatostatin. In early stages of ARM, the choroidal vasculature and neuroretinal tissue stained identical to control tissue. We found no expression of sst_{2A} in BLD or drusen, which is in contrast with findings for other angiogenic growth factors like VEGF.

[0047] In eyes with exudative AMD, we found increased expression of sst_{2A} in endothelial cells and fibroblast-like cells in early CNV. The expression of sst_{2A} in newly formed capillaries was abundant in fibrovascular CNV membranes. Similarly, in the active component of mixed fibrovascular/fibrocellular CNV, sst_{2A} was highly expressed in endothelial cells.

[0048] The angiogenic cells of CNV membranes are capable of receiving angiogenic inhibition, directly receptor mediated or indirectly via inhibition of GH and IGF-I by somatostatin.

[0049] Furthermore, strong positive sst_{2A} expression in fibroblast-like cells and macrophages in fibrovascular CNV and in intrachoroidal myofibroblasts is found. Sst_{2A} staining in myofibroblasts may be due to cross-reactivity to myosin (See: Reubi JC, Laissue JA, Waser B, *et al.*, "Immunohistochemical detection of somatostatin sst_{2A} receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: fact and artifacts", *J Chin Endocrinol Metab.* 1999;84:2942-2950), but macrophages have been shown to express sst_{2A} (See: Ten Bokum AMC, Hofland LJ, de Jong G, *et al.* "Immunohistochemical localization of somatostatin receptor sst_{2A} in sarcoid granulomas", *Eur J Clin Invest.* 1999;29:630-636).

[0050] In the overlying neuroretina of eyes with CNV, no obvious change of sst_{2A} expression and localization in comparison to normal eyes was observed. This is in contrast to VEGF expression in neuronal tissue, which is upregulated under hypoxic circumstances (See: Kliffen M, Sharma HS, Mooy CM, *et al.* "Increased expression of angiogenic growth factors in age-related maculopathy", *Br J Ophthalmol.* 1997;81:154-162 and Pe'er J, Shweiki D, Itin A, *et al.* "Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases", *Laboratory Investigation.* 1995;72:638-644). This indicates that the function of somatostatin on neuronal tissue is not influenced by hypoxic retinal disease.

[0051] From these results it follows that somatostatin and VEGF have distinct functions in the control of angiogenesis.

[0052] Local synthesis of sst_{2A} in the macula of normal human eyes was confirmed with RT-PCR. Also, the expression of mRNA encoding for sst subtypes 1 and 3 was demonstrated.

[0053] mRNA expression of the neuropeptide somatostatin in the human macula was observed. The production of both somatostatin and its receptors simultaneously suggests an autocrine action of somatostatin in the human retina, which finding is used in the medicament of the present invention.

5 Claims

1. Use of a compound that binds to at least one somatostatin receptor in the eye in the manufacture of a medicament for the treatment of a choroidal neovascularization (CNV) related disorder.
2. Use according to claim 1, wherein said compound binds to a somatostatin 2A receptor (sst_{2A}).
3. Use according to any of the previous claims, wherein the CNV related disease is exudative age-related macular degeneration (AMD).
4. Use according to any of the previous claims, wherein said compound is selected from the group consisting of somatostatin and somatostatin analogues.
5. Use according to claim 4, wherein the somatostatin analogue is selected from the group consisting of octreotide, vapreotide and lanreotide.
6. Use according to any of the previous claims, wherein said medicament is formulated for topical administration.
7. Use according to any of the previous claims, wherein said medicament is in the form selected from the group consisting of eye drops, eye gel and eye ointment.
8. Use according to any of claims 1-5, wherein said medicament is formulated for subcutaneous or intramuscular administration, preferably in slow release form.
9. A method for treating choroidal neovascularization or disorder related or associated therewith, comprising administering a compound that binds to at least one somatostatin receptor in the eye.
10. The method of claim 9, wherein the said compound is administered on or in the eye.

Fig. 1




Fig. 2



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 040 837 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
02.01.2002 Bulletin 2002/01

(43) Date of publication A2:
04.10.2000 Bulletin 2000/40

(21) Application number: 00200707.8

(22) Date of filing: 28.02.2000

(51) Int Cl.7: **A61K 38/31**, A61K 9/06,
A61K 9/52, A61K 9/08,
A61K 9/10, A61P 27/02

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 26.02.1999 US 258240

(71) Applicant: Erasmus Universiteit Rotterdam
3015 GE Rotterdam (NL)

(72) Inventors:
• Kuijpers, Robertus Wilhelmus Aloysius Maria
3023 BG Rotterdam (NL)
• van Hagen, Petrus Martinus
3062 XM Rotterdam (NL)
• Baarsma, Goitzen Seerp
3054 CM Rotterdam (NL)

(74) Representative: Ottevangers, Sietse Ulbe et al
Vereenigde, Nieuwe Parklaan 97
2587 BN The Hague (NL)

(54) **Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder**

(57) The invention relates to preparation of medicaments for the treatment of ocular disorders, in particular choroidal neovascularization (CNV) related disorders. The control of ocular neovascularization is regulated by

a balance between stimulating and inhibiting growth factors. The anti-angiogenic effect of somatostatin analogues are used to provide a medicament for the treatment of a choroidal neovascularization (CNV) related disorder.

EP 1 040 837 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 20 0707

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	ROBERTSON JOSEPH E ET AL: "Intravitreal injection of octreotide acetate." JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 13, no. 2, 1997, pages 171-177, XP002182206 ISSN: 1080-7683 * the whole document *	1,2,4-6, 9,10	A61K38/31 A61K9/06 A61K9/52 A61K9/08 A61K9/10 A61P27/02
X	WO 98 45285 A (PASTERNAK ALEXANDER ;PATCHETT ARTHUR A (US); CHAPMAN KEVIN (US); Y) 15 October 1998 (1998-10-15) * page 1, line 27 - page 2, line 20 * * page 41, line 11 - page 43, line 9 * * page 44, line 20 - line 26 * * page 93, line 14 - page 94, line 3 * * claims 30,31 *	1,2,4, 6-10 3	
Y			
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		7 November 2001	Stein, A
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>			

EPO FORM 1533 03.02 (P0407)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 00 20 0707

Although claims 9 and 10 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched completely:
4,5

Claim(s) searched incompletely:
1-3,6-10

Reason for the limitation of the search:

Present claims 1-3 and 6-10 relate to a compounds defined by reference to a desirable property, namely its binding to somatostatin receptor in the eye without giving any structural or essential characteristics of the compound.

The claims cover all compounds having this property, whereas the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in the description at page 4 line 14-page 5 line 10, page 8 lines 3-36 and in claims 4 and 5.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 00 20 0707

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y,D	SMITH LOIS E H ET AL: "Essential role of growth hormone in ischemia-induced retinal neovascularization." SCIENCE (WASHINGTON D C), vol. 276, no. 5319, 1997, pages 1706-1709, XP002182207 ISSN: 0036-8075 * the whole document *	3	
A	GRANT MARIA B ET AL: "Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: A potential treatment for ocular neovascularization." REGULATORY PEPTIDES, vol. 48, no. 1-2, 1993, pages 267-278, XP001031269 ISSN: 0167-0115 * the whole document *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
P,X	WO 00 06185 A (MOREAU JACQUES PIERRE ;BIOMEASURE INC (US)) 10 February 2000 (2000-02-10) * the whole document *	1-10	
E	CA 2 263 042 A (KUIJPERS RWA, BAARSMA S, VAN HAGEN MP) 25 August 2000 (2000-08-25) * the whole document *	1-10	
E	WO 00 12111 A (UNIV BRITISH COLUMBIA ;BUCHAN ALISON (CA); HSIANG YORK (CA); LEVY) 9 March 2000 (2000-03-09) * page 4, line 10 - line 12 * * page 4, line 28 - page 5, line 4 * * page 5, line 27 - page 6, line 31 * * page 20, line 18 - page 22, line 14 * * claims 1,2,4,5,10,12,13,18,20-23 * — -/-	1,3,4, 6-10	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 20 0707

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
T	<p>LANBOOIJ A C ET AL: "SOMATOSTATIN RECEPTOR 2A EXPRESSION IN CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION" INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 41, no. 8, July 2000 (2000-07), pages 2329-2335, XP000990309 ISSN: 0146-0404</p> <p>* the whole document *</p>	1-10	
T	<p>HAGEN VAN P M ET AL: "SOMATOSTATIN AND SOMATOSTATIN RECEPTORS IN RETINAL DISEASES" EUROPEAN JOURNAL OF ENDOCRINOLOGY, SCANDINAVIAN UNIVERSITY PRESS, NO, vol. 143, October 2000 (2000-10), pages S43-S51, XP000990364 ISSN: 0804-4643</p> <p>* the whole document *</p>	1-10	<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>

EPO FORM 1503 02/95 (P4/C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 20 0707

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-11-2001

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9845285	A	15-10-1998	AU	6946098 A	30-10-1998
			EP	0977751 A1	09-02-2000
			US	6025372 A	15-02-2000
			WO	9845285 A1	15-10-1998
WO 0006185	A	10-02-2000	AU	5244799 A	21-02-2000
			BR	9912609 A	02-05-2001
			EP	1100532 A2	23-05-2001
			NO	20010481 A	21-03-2001
			WO	0006185 A2	10-02-2000
			US	6150333 A	21-11-2000
CA 2263042	A		NONE		
WO 0012111	A	09-03-2000	AU	5499799 A	21-03-2000
			WO	0012111 A2	09-03-2000
			CN	1320042 T	31-10-2001
			EP	1107780 A2	20-06-2001
			NO	20011025 A	30-03-2001

EPO FORM P4489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82